发明名称 |
Methods for cancer management targeting Co-029 |
摘要 |
The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient. |
申请公布号 |
US9487586(B2) |
申请公布日期 |
2016.11.08 |
申请号 |
US201514691630 |
申请日期 |
2015.04.21 |
申请人 |
Institut National de la Santé et de la Recherche Médicale (INSERM);UNIVERSITE DE PARIS XI PARIS SUD |
发明人 |
Rubinstein Eric;Greco Céline;Le Naour François;Boucheix Claude |
分类号 |
A61K39/395;C07K16/28;C07K16/30;C12N15/113;G01N33/574;C12N5/09;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
Whitham, Curtis & Cook, P.C. |
代理人 |
Whitham, Curtis & Cook, P.C. |
主权项 |
1. A method of treating a Co-029-expressing cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a Co-029 antibody directed against human Co-029, wherein the Co-029 antibody comprises the six complementarity determining region (CDR) sequences of an antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4046 or the six complementarity determining region (CDR) sequences of an antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4047. |
地址 |
Paris FR |